230 related articles for article (PubMed ID: 33979560)
1. Fatal cerebral hemorrhage in a patient with thrombotic thrombocytopenic purpura with a normal platelet count during treatment with caplacizumab.
Ditzel K; Mons DJ; Fijnheer R
Platelets; 2022 Apr; 33(3):484-485. PubMed ID: 33979560
[TBL] [Abstract][Full Text] [Related]
2. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
[TBL] [Abstract][Full Text] [Related]
3. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK;
N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
Goshua G; Sinha P; Hendrickson JE; Tormey C; Bendapudi PK; Lee AI
Blood; 2021 Feb; 137(7):969-976. PubMed ID: 33280030
[TBL] [Abstract][Full Text] [Related]
5. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.
Elverdi T; Eskazan AE
Drug Des Devel Ther; 2019; 13():1251-1258. PubMed ID: 31118566
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.
Knoebl P; Cataland S; Peyvandi F; Coppo P; Scully M; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Minkue Mi Edou J; De Winter H; Callewaert F
J Thromb Haemost; 2020 Feb; 18(2):479-484. PubMed ID: 31691462
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab.
Völker LA; Brinkkoetter PT; Knöbl PN; Krstic M; Kaufeld J; Menne J; Buxhofer-Ausch V; Miesbach W
J Thromb Haemost; 2020 Nov; 18(11):3061-3066. PubMed ID: 32757435
[TBL] [Abstract][Full Text] [Related]
8. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Cataland S; Knöbl P; Wu H; Artoni A; Westwood JP; Mansouri Taleghani M; Jilma B; Callewaert F; Ulrichts H; Duby C; Tersago D;
N Engl J Med; 2016 Feb; 374(6):511-22. PubMed ID: 26863353
[TBL] [Abstract][Full Text] [Related]
9. Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura.
Bergstrand M; Hansson E; Delaey B; Callewaert F; De Passos Sousa R; Sargentini-Maier ML
J Clin Pharmacol; 2022 Mar; 62(3):409-421. PubMed ID: 34699078
[TBL] [Abstract][Full Text] [Related]
10. A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.
Gómez-Seguí I; Fernández-Zarzoso M; de la Rubia J
Expert Rev Hematol; 2020 Nov; 13(11):1153-1164. PubMed ID: 32876503
[No Abstract] [Full Text] [Related]
11. Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura.
Shaffer J; Grove A
Platelets; 2022 Jul; 33(5):790-791. PubMed ID: 34565299
[TBL] [Abstract][Full Text] [Related]
12. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial).
Estcourt LJ
Transfus Med; 2019 Jun; 29(3):146-148. PubMed ID: 31318128
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura.
Sargentini-Maier ML; De Decker P; Tersteeg C; Canvin J; Callewaert F; De Winter H
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):537-545. PubMed ID: 30977686
[No Abstract] [Full Text] [Related]
14. Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment.
Palanques-Pastor T; Megías-Vericat JE; Bosó Ribelles V; Gómez Seguí I; Poveda Andrés JL
Acta Haematol; 2022; 145(1):72-77. PubMed ID: 34352748
[TBL] [Abstract][Full Text] [Related]
15. Thrombotic thrombocytopenic purpura in caplacizumab era - An individualized approach.
Sarode R
Transfus Apher Sci; 2023 Apr; 62(2):103682. PubMed ID: 36890095
[TBL] [Abstract][Full Text] [Related]
16. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
Völker LA; Kaufeld J; Miesbach W; Brähler S; Reinhardt M; Kühne L; Mühlfeld A; Schreiber A; Gaedeke J; Tölle M; Jabs WJ; Özcan F; Markau S; Girndt M; Bauer F; Westhoff TH; Felten H; Hausberg M; Brand M; Gerth J; Bieringer M; Bommer M; Zschiedrich S; Schneider J; Elitok S; Gawlik A; Gäckler A; Kribben A; Schwenger V; Schoenermarck U; Roeder M; Radermacher J; Bramstedt J; Morgner A; Herbst R; Harth A; Potthoff SA; von Auer C; Wendt R; Christ H; Brinkkoetter PT; Menne J
Blood Adv; 2020 Jul; 4(13):3085-3092. PubMed ID: 32634236
[TBL] [Abstract][Full Text] [Related]
17. Real-world experience with caplacizumab in the management of acute TTP.
Dutt T; Shaw RJ; Stubbs M; Yong J; Bailiff B; Cranfield T; Crowley MP; Desborough M; Eyre TA; Gooding R; Grainger J; Hanley J; Haughton J; Hermans J; Hill Q; Humphrey L; Lowe G; Lyall H; Mohsin M; Nicolson PLR; Priddee N; Rampotas A; Rayment R; Rhodes S; Taylor A; Thomas W; Tomkins O; Van Veen JJ; Lane S; Toh CH; Scully M
Blood; 2021 Apr; 137(13):1731-1740. PubMed ID: 33150355
[TBL] [Abstract][Full Text] [Related]
18. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
[TBL] [Abstract][Full Text] [Related]
19. Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura.
Reid JH; Durant KM; Chen SL; Perissinotti AJ; King R; Khoriaty R; Marini BL
J Oncol Pharm Pract; 2020 Oct; 26(7):1695-1702. PubMed ID: 32605495
[TBL] [Abstract][Full Text] [Related]
20. Refractory acquired thrombotic thrombocytopenic purpura in a patient with sickle cell trait successfully treated with caplacizumab.
Aggarwal V; Singer Z; Ledingham D; Othman I
Hematology; 2021 Dec; 26(1):590-593. PubMed ID: 34396933
[No Abstract] [Full Text] [Related]
[Next] [New Search]
